A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: VX-509 matching placebo
- Registration Number
- NCT01754935
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Brief Summary
The current study is designed to evaluate the safety and efficacy, including MRI imaging, across a range of VX-509 doses in subjects with active rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs).
- Detailed Description
VX-509 is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex. In autoimmune diseases, JAK3 is an essential component of the immune signaling cascade. This cascade ultimately contributes to abnormal immune response that results in chronic inflammation and, in the case of rheumatoid arthritis (RA), irreversible damage to cartilage and bones. Selective inhibition of JAK3 offers a new disease modifying approach to the treatment of RA, and a broad range of other autoimmune diseases.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
- Male and female subjects 18 to 65 years of age (inclusive)
- Diagnosis of RA
- Swollen joint count of ≥6 out of 66 joints and tender joint count of ≥6 out of 68 joints
- Seropositivity based on either a positive rheumatoid factor or anti cyclic citrullinated peptide antibody at screening -OR- known erosive disease based on previous X-ray report or erosions detected on screening hand and foot X-ray
- Baseline CRP level or Westergren erythrocyte sedimentation rate ≥1.2 × upper limit of normal
- Receiving stable therapy with 1 of the following DMARDs: methotrexate, sulfasalazine, leflunomide, anti-malarial drug, or penicillamine
- Palpable 2+ synovitis of the wrist or ≥2 MCPs in the MRI-designated hand
Exclusion Criteria
- History or presence of a clinically significant medical disorder other than RA that, in the opinion of the investigator and medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
- Inflammatory, rheumatological disorders other than RA, where arthritis may be a prominent feature
- Planned surgery during the study
- History of alcohol or drug abuse, or excessive alcohol consumption
- History of tuberculosis (TB) infection of any kind (pulmonary or extrapulmonary, active or latent), regardless of history of anti-TB treatment.
- Pregnant or nursing an infant or with a life partner who is pregnant, nursing, or planning to become pregnant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description VX-509 300 mg qd Arm VX-509 - Placebo Arm VX-509 matching placebo - VX-509 100 mg qd Arm VX-509 - VX-509 200 mg qd Arm VX-509 -
- Primary Outcome Measures
Name Time Method Change from baseline in Disease Activity Score 28 using CRP (4-component) (DAS28-4[CRP]) Week 12 Change from baseline in OMERACT RAMRIS synovitis score in designated hand wrist Week 12 Proportion of subjects achieving a ≥20% improvement in disease severity according to the American College of Rheumatology criteria (ACR20), using C reactive protein (CRP) (ACR20 CRP) Week 12 Change from baseline in OMERACT RAMRIS bone marrow edema (osteitis) in designated hand wrist Week 12 Change from baseline in OMERACT RAMRIS erosion score in designated hand wrist Week 12
- Secondary Outcome Measures
Name Time Method Change from baseline in Health Assessment Questionnaire -Disability Index (HAQ-DI) Week 12 Proportion of subjects achieving a ACR50 CRP and ACR70 CRP responses Week 12 Proportion of subjects with DAS28 CRP <2.6, and those who achieve a remission, moderate response or good response according to the European League Against Rheumatism (EULAR) response criteria Week 12 Safety and tolerability as indicated by adverse events, laboratory tests, electrocardiograms (ECGs) and vital signs Week 12 Change from baseline in the Physical Component and Mental Health Components of the SF-36 Week 12 PK parameters of VX-509 and its metabolite in plasma (maximum observed concentration [Cmax] and area under the concentration versus time curve [AUC]) Week 12 Change from baseline in the Physical Function subscale of the 36-item Short Form (SF-36) Week 12 ACR hybrid scores Week 12 Change from baseline in OMERACT RAMRIS synovitis, bone marrow edema (osteitis), erosion scores Week 6
Trial Locations
- Locations (1)
Vertex Investigational Site
🇿🇦Stellenbosch, South Africa